View in EDS

Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.

Saved in:
Bibliographic Details
Title: Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Authors: Sheng W; Division of Newborn Medicine and Epigenetics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. wanqiang_sheng@zju.edu.cn yang.shi@ludwig.ox.ac.uk., Liu Y; Division of Newborn Medicine and Epigenetics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Chakraborty D; Division of Newborn Medicine and Epigenetics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Debo B; Division of Newborn Medicine and Epigenetics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Shi Y; Division of Newborn Medicine and Epigenetics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. wanqiang_sheng@zju.edu.cn yang.shi@ludwig.ox.ac.uk.; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
Source: Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1970-1981. Date of Electronic Publication: 2021 Mar 09.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-20-0017